With GLP-1 receptor agonists (GLP-1 RAs) gaining popularity for managing type 2 diabetes and promoting weight loss, many people are looking for oral (non-injection) options. While most GLP-1 drugs are injectable, there is one FDA-approved oral GLP-1 drug currently available.
Oral GLP-1 Drugs List
1. Semaglutide (Brand Name: Rybelsus)
- Form: Oral tablet
- Approved for: Type 2 diabetes
- Strengths: 3 mg, 7 mg, 14 mg
- Mechanism: Mimics GLP-1 hormone, lowers blood sugar, promotes satiety
- Manufacturer: Novo Nordisk
Rybelsus is the first and only oral GLP-1 receptor agonist approved by the FDA (since 2019). It offers a needle-free option for those who are hesitant about injections.
Are There Other Oral GLP-1 RAs?
As of now (2025), Rybelsus (semaglutide) is the only GLP-1 RA available in oral form. However, pharmaceutical companies are actively developing new oral versions and combinations, including:
- Oral tirzepatide (under research)
- Orforglipron (Eli Lilly)
- Status: Phase 3 clinical trials completed for type 2 diabetes; ongoing for obesity and other indications.
- NN-9932 (Novo Nordisk)
- Status: Phase 3 trials for obesity.
- Aleniglipron (Structure Therapeutics)
- Status: Phase 2b trials for obesity and type 2 diabetes.
- ECC5004/AZD5004 (Eccogene/AstraZeneca)
- Status: Phase 2 trials for type 2 diabetes and obesity.
Discontinued or Halted Oral GLP-1 Drugs
- Danuglipron (Pfizer)
- Status: Discontinued as of April 14, 2025.
Final Note
If you’re looking for an oral alternative to injectable weight loss or diabetes medications, Rybelsus is currently your best bet. It combines the effectiveness of GLP-1 action with the convenience of a once-daily pill.
Always consult your doctor to see if oral GLP-1 therapy is right for you.